Regentis Biomaterials (NYSE American: RGNT) announced that the Japan Patent Office has issued a Notice of Allowance for a patent covering its proprietary organic solvent-free manufacturing process and ready-to-use liquid formulation used in GelrinC, the company’s regenerative treatment for articular cartilage injuries. This allowance expands Regentis’ global intellectual property portfolio as it advances GelrinC commercialization in Europe, continues enrollment in its pivotal U.S. clinical trial, and evaluates expansion into additional international markets.
The allowed patent covers proprietary protein-polymer conjugate compositions and manufacturing methods designed to eliminate the use of organic solvents while enabling stable liquid formulations. According to the company, the technology improves manufacturing efficiency, increases production yield, simplifies manufacturing, and enhances scalability for commercial production. Regentis said the patent also strengthens its position in Japan, one of the world’s largest cartilage repair markets, where demand is expected to grow as the population ages and the prevalence of knee osteoarthritis increases.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. GelrinC, a cell-free, off-the-shelf hydrogel, is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is available.
The patent allowance in Japan is a significant step for Regentis as it seeks to protect its innovative manufacturing technology globally. The company’s focus on eliminating organic solvents aligns with regulatory trends favoring greener processes. With Japan’s aging population and rising knee osteoarthritis cases, the market potential for GelrinC is substantial. Regentis continues to execute its strategy, with European commercialization underway and a U.S. pivotal trial enrolling patients. The company’s newsroom provides updates on its progress at https://ibn.fm/RGNT.
